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A 59-year-old woman was seen in the clinic for evaluation of an adrenal mass.
Two years earlier, she had undergone her first physical examination since childhood,
having sought medical attention because of morning stiffness and polyarticular joint
pain that she had had for several months and the recent onset of dysuria. She was found to
have hypertension (blood pressure, 140/100 mm Hg) and rheumatoid arthritis. A urine
culture showed growth of 
 
Escherichia coli
 
, and amoxicillin was prescribed. Doxazosin
(4 mg) and lisinopril (10 mg) were administered for the hypertension; her arthritis
symptoms were controlled by hydroxychloroquine.
Dysuria, pyuria, and positive urine cultures persisted, despite multiple courses of
antibiotics. Five months after the physical examination, a computed tomographic (CT)
scan of the pelvis showed a colovesical fistula. There was a well-circumscribed, homo-
geneous mass, 2.5 cm in diameter, in the left adrenal gland. A low anterior resection of
the rectum and excision and closure of the colovesical fistula were performed. Over the
next year, the patient gained 7 kg in weight and remained hypertensive despite increas-
ing doses of antihypertensive medications. An abdominal–pelvic CT scan obtained 17
months after the first scan showed that the left adrenal mass was unchanged in size
and appearance and the density was measured at 4 Hounsfield units. The patient was
referred to an endocrinologist.
The patient was unmarried and had never been sexually active. Menopause occurred
when she was 47 years of age. She had smoked three packs of cigarettes per day for 40
years but had stopped 4 years earlier, at 55 years of age. She consumed approximately
one alcoholic beverage per week. There was no family history of endocrine disorders or
tumors. Her medications were lisinopril (20 mg daily), hydroxychloroquine (20 mg twice
daily), doxazosin (8 mg daily), and nifedipine (60 mg daily).
The patient’s blood pressure was 150/90 mm Hg, and her pulse 80 beats per minute
and regular; her weight was 109 kg. At the examination by the endocrinologist, mild
facial plethora and fullness were evident. There was no hirsutism. There were dorso-
cervical and supraclavicular fat pads. There was no bruising of the soft tissue. The thyroid
gland was not enlarged. Examination of the abdomen showed truncal obesity without
striae. There was no organomegaly. Neurologic examination showed no abnormalities,
and there was no proximal limb weakness.
presentation of case
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A complete blood count, levels of serum electro-
lytes, and the results of tests of renal, liver, and thy-
roid function were all normal. After the adminis-
tration of 1 mg of dexamethasone in the evening,
the morning cortisol measurement was 2.2 µg per
deciliter. On multiple examinations, all performed
in the morning during a two-month period, the
levels of corticotropin ranged from 11 to 40 pg per
milliliter (2.4 to 8.8 pmol per liter); the normal
range is 6 to 76 pg per milliliter (1.3 to 16.7 pmol per
liter). The results of other hormone tests are shown
in Tables 1, 2, and 3.
A CT scan of the patient’s head after intrave-
nous administration of contrast material showed
a partially empty sella turcica and no signs of a pitu-
itary adenoma. A chest radiograph showed no ab-
normalities.
A diagnostic procedure was performed.
 
Dr. Robert G. Dluhy:
 
 May we review the imaging of
the adrenal mass?
 
Dr. Michael M. Maher:
 
 The original CT scan shows
a left adrenal mass, 2.5 cm in diameter; the density
of the lesion appears low (Fig. 1A). The scan from
17 months later again shows a well-circumscribed,
low-density mass, 2.5 cm in diameter, that has re-
mained stable in size (Fig. 1B). The density of the
lesion was measured at 4 Hounsfield units, which
suggests the presence of fat and a diagnosis of
an adrenal adenoma. The right adrenal gland is
normal.
 
Dr. Dluhy:
 
 This 59-year-old, postmenopausal, hy-
pertensive woman with recurrent urinary tract infec-
tions was incidentally found to have a left adrenal
mass, 2.5 cm in diameter, during a CT examination
of the abdomen and pelvis. Seventeen months later,
she had gained 7 kg and remained hypertensive even
though she was taking three drugs to lower her
blood pressure. The findings on physical examina-
tion suggested Cushing’s syndrome, with truncal
obesity and palpable supraclavicular and dorsocer-
vical fat pads, but there were no signs of abdominal
striae, proximal limb weakness, or hirsutism. A CT
scan obtained at the time of the visit to the endocri-
nologist showed that the left adrenal mass had not
enlarged. The mass was homogeneous and of low
density, findings consistent with the diagnosis of a
cortical adenoma.
The term “incidentaloma” has been coined for an
adrenal mass that is discovered during diagnostic
testing for another condition, rather than testing
performed because of the suspicion of an adrenal
disorder.
 
1
 
 Benign adrenal masses of 1 to 2 cm in
size are found in 2 to 3 percent of adults older than
50 years of age who are examined at autopsy. The
prevalence of clinically inapparent adrenal masses
increases with age and approaches 7 percent among
persons older than 70 years of age. Conversely, in-
cidentalomas are uncommon in patients younger
than 30 years of age; thus, an adrenal mass in a
young patient is probably clinically important.
In the evaluation of an adrenal mass, there are
two issues that need to be addressed. First, is the
mass benign or malignant? Second, if it is a primary
adrenal tumor, is it functional — is it secreting hor-
mones or not? In this case, the issue is whether the
mass is causing severe hypertension and the physi-
cal features that suggest Cushing’s syndrome.
differential diagnosis
 
* NA denotes not available.
 
Table 1. Urinary Hormone Levels.*
Variable Day 1 Day 3 Day 16 Day 61
Normal 
Values
 
Free cortisol (µg/24 hr) 20 110 96 73 20–70 
Total volume (ml/24 hr) 1050 1600 2000 1320
Creatinine (mg/24 hr) NA NA 1460 1056
Epinephrine (µg/24 hr) 5 2–24 
Norepinephrine (µg/24 hr) 51 15–100 
Total catecholamines (µg/24 hr) 56 20–121 
Metanephrine (µg/24 hr) 127 45–290 
Normetanephrine (µg/24 hr) 375 82–500 
Total metanephrines (µg/24 hr) 502 120–700 
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benign or malignant?
 
Seventy-five percent of adrenal masses detected dur-
ing staging in a patient with cancer represent me-
tastases.
 
1
 
 Such masses usually have high CT atten-
uation values (>20 Hounsfield units), in contrast
to the adrenal mass in this patient. For a cortical
neoplasm, such as this mass, the first concern is
whether it is an adrenal cortical carcinoma. This
is a very rare cancer, with an estimated prevalence
of 5 cases per 1 million persons, but it has a high
associated mortality rate. The risk that the tumor
will be a carcinoma increases with the size of the
tumor.
 
2
 
 The risk of cancer is 2 percent among tu-
mors less than 4 cm in diameter, but it increases to
25 percent for tumors greater than 6 cm. Accord-
ingly, most clinicians recommend excision of adre-
nal masses greater than 6 cm. There is controversy
as to whether neoplasms from 4 to 6 cm in size
should be removed; the overwhelming majority are
benign, but the risk of cancer is 6 percent. Other
radiographic features that may indicate a benign
neoplasm include smooth borders without evidence
of hemorrhage or necrosis.
The neoplasm in this patient was 2.5 cm in diam-
eter and was described as well circumscribed and
homogeneous. Most important, over the course of
17 months, the mass had not changed in size or ap-
pearance. Periodic radiographic surveillance, such
as every six months over a period of several years,
of patients with small adrenal masses that carry a
low risk of cancer,  such as this one, is an accepted
strategy to ascertain with some confidence whether
the lesion is benign.
 
3
 
 Although some benign mass-
 
* This is the normal range for postmenopausal women.
 
Table 2. Serum Hormone Levels.
Variable Value Normal Value
 
Renin (ng/ml/hr) 12.2 0.7–10.0
Aldosterone (ng/dl) 7.0 2–9
Dehydroepiandrosterone
sulfate (µg/dl)
37 30–260*
 
*This test was performed in the morning.
 
Table 3. Corticotropin-Releasing Hormone Stimulation 
Test (1 µg per Kilogram of Body Weight).*
Time in Relation
to Stimulation Corticotropin Cortisol
 
min pg/ml µg/dl
 
¡15 12 14
0 14 12 
15 33 23
30 40 31
60 33 37
90 25 31
120 16 26
 
Figure 1. CT Scan of the Abdomen Obtained without 
the Administration of Intravenous Contrast Material.
 
A CT scan of the abdomen obtained 17 months before 
the current evaluation (Panel A) shows a left adrenal mass, 
2.5 cm in diameter (arrow), which is well circumscribed 
and is of low density. A CT scan obtained at the time of 
this evaluation (Panel B) shows a well-circumscribed, 
low-density left adrenal lesion that is stable in size and 
appearance on imaging as compared with the previous 
image. The density of the left adrenal mass (arrow and cir-
cle) is 4 Hounsfield units. The right adrenal gland shows 
no abnormalities (arrowhead).
A
B
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es can increase in size over time, a mass that increas-
es in size by more than 2 cm over 6 to 12 months
should probably be surgically removed. All of the
radiographic data support the diagnosis of a benign
adrenocortical adenoma in this patient.
 
functional or nonfunctional?
 
The next consideration is whether the adrenal mass
is clinically functional, since surgical removal of the
mass could be indicated if there is hormonal hyper-
secretion. Approximately 70 percent of clinically in-
apparent adrenal masses are nonfunctional. Since
this patient had severe hypertension and physical
features that suggested Cushing’s syndrome, a
unifying diagnosis would be a cortisol-secreting
adenoma.
Functional adrenal tumors include pheochromo-
cytomas, cortisol-secreting adenomas, aldosterone-
secreting adenomas, and neoplasms that have viril-
izing or feminizing effects. The first step in patients
with clinically inapparent adrenal masses should
be to review the history and physical examination,
searching for clues to excessive hormone secretion.
The presence of hypertension, a history of paroxys-
mal hypertension, and symptoms and signs of hy-
persecretion of cortisol and sex hormones should
be sought. Even in the absence of these findings,
a National Institutes of Health State-of-the-Science
Conference recommended that all patients with in-
cidentally discovered adrenal masses be screened
for pheochromocytoma and hypercortisolism.
 
1
 
 Pa-
tients with hypertension should also be evaluated
for primary hyperaldosteronism.
Catecholamine levels were assessed in this pa-
tient with a 24-hour urine specimen, and they were
normal (Table 1). Screening for primary aldosteron-
ism is performed by the simultaneous measurement
of plasma renin activity and plasma aldosterone.
A plasma aldosterone-to-renin ratio greater than
25 to 30 is consistent with autonomous aldosterone
secretion.
 
4
 
 In this patient, the plasma renin level was
not suppressed and was appropriately elevated, a re-
flection of angiotensin-converting–enzyme inhibi-
tion (Table 2). Finally, the level of the adrenal andro-
gen dehydroepiandrosterone sulfate was normal.
In summary, I can confidently conclude that the
adrenal mass in the patient under discussion was
not a pheochromocytoma or an aldosterone- or
androgen-producing neoplasm.
To diagnose Cushing’s syndrome, the overnight
dexamethasone suppression test is preferred. After
the administration of 1 mg of dexamethasone at
bedtime, the measurement the next morning of a
cortisol level less than 1.8 µg per deciliter rules out
Cushing’s syndrome.
 
5
 
 This criterion results in a test
with high sensitivity but a high false positive rate.
An alternative test with high sensitivity and speci-
ficity is the measurement of free or unmetabolized
cortisol in a 24-hour urine specimen. False positive
results in either test can occur in patients with de-
pression and chronic alcoholism; however, such pa-
tients may not have physical features of Cushing’s
syndrome. Subclinical hypercortisolism also may
occur somewhat frequently in incidentally discov-
ered adrenal masses (so-called preclinical Cushing’s
syndrome).
 
6-8
 
The data in this patient are inconsistent. The
level of cortisol (2.2 µg per deciliter) the morning
after the dexamethasone suppression test was prob-
ably normal. However, the free cortisol level in the
24-hour urine specimen shows intermittent hyper-
cortisolism, although levels of creatinine excretion
are not provided to validate the accuracy of some of
the specimens (Table 1). Considering the clinical
features that suggested Cushing’s syndrome and the
possibility of a cortisol-secreting adrenal neoplasm,
evaluation was pursued on the basis of the reason-
ing that adrenal hypercortisolism should be associ-
ated with suppressed levels of corticotropin. Early-
morning plasma levels of corticotropin greater than
20 pg per milliliter (4.4 pmol per liter) imply a corti-
cotropin-dependent cause, and levels less than 5 pg
per milliliter (1.1 pmol per liter) an adrenal-depen-
dent cause; levels between 5 and 20 pg per milliliter
are considered indeterminate.
 
5
 
 In this patient, the
morning levels of corticotropin varied, ranging from
11 to 40 pg per milliliter.
Next, an ovine corticotropin-releasing hormone
stimulation test was performed (Table 3). In patients
with Cushing’s disease secondary to a pituitary mi-
croadenoma, the increment in levels of corticotro-
pin above the baseline level exceeds 50 percent; ec-
topic corticotropin-secreting tumors usually fail to
respond to stimulation with corticotropin-releasing
hormone.
 
5,9
 
 In this patient, the baseline level of
corticotropin more than doubled, but the absolute
peak level of 40 pg per milliliter at 30 minutes is at
the low end of the responses in normal subjects. The
cortisol levels appropriately followed the changes
in corticotropin. Taken together, the data are prob-
ably best interpreted as showing intermittent hyper-
cortisolism with incomplete suppression of pitu-
itary secretion of corticotropin.
The expression of ectopic hormone receptors
The New England Journal of Medicine 
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in the adrenal cortex could explain the varied bio-
chemical data in this patient.
 
10,11
 
 This phenomenon
is usually seen in patients with bilateral macronod-
ular adrenal hyperplasia, but cases of unilateral
adrenal adenomas with ectopic hormone receptors
have been reported.
 
4
 
 Ectopic receptors that can
be expressed include gastric inhibitory polypep-
tide,
 
12,13
 
 luteinizing hormone,
 
14
 
 and catechola-
mines.
 
15
 
 The hypercortisolism in patients with
adrenal ectopic receptor expression may be episod-
ic — for example, occurring after meals — and in
most cases the corticotropin levels are frankly sup-
pressed. However, adrenal neoplasms with inter-
mittent food-related hypercortisolism and incom-
plete suppression of corticotropin have also been
reported.
 
16
 
I conclude that the hypercortisolism in this pa-
tient is corticotropin-independent and that the left
adrenal adenoma is secreting cortisol episodically.
The secretion of cortisol is at a level that is sufficient
to produce the clinical features of Cushing’s syn-
drome but it is insufficient to suppress corticotropin
levels completely. The episodic nature of the secre-
tion best fits the characteristics associated with
food-dependent Cushing’s syndrome; the measure-
ment of cortisol levels after a meal could have been
an appropriate diagnostic test. Alternatively, there
could be intrinsic episodic secretion by the tumor
or expression of another ectopic receptor.
To confirm the diagnosis, the function of the
contralateral adrenal gland could be assessed with
the use of scintigraphy with radiolabeled iodocho-
lesterol. This test shows exclusive uptake in the
gland with the tumor and no visualization of the
contralateral gland in patients with hypercortisol-
ism due to an adenoma.
 
17,18
 
 An alternative test
would be bilateral adrenal-vein sampling to docu-
ment lateralization of cortisol secretion on the side
of the adenoma.
 
Dr. Nancy Lee Harris 
 
(Pathology): Dr. Grinspoon,
can you tell us what your thinking was as you eval-
uated this patient?
 
Dr. Steven K. Grinspoon 
 
(Endocrinology): This pa-
tient had a 2.5-cm adrenal mass that had been sta-
ble in size for 17 months. She did not show many
of the typical stigmata associated with Cushing’s
syndrome and, on the basis of the physical exami-
nation, could have been considered to have simple
obesity. The results of the biochemical testing were
equivocal: in the overnight 1-mg dexamethasone
test, her morning cortisol level was suppressed to
2.2 µg per deciliter, but three of four measurements
of free cortisol levels in the urine were increased.
Her level of corticotropin, although low, was not en-
tirely suppressed. On the corticotropin-releasing
hormone test, she had increases in cortisol and cor-
ticotropin that were more consistent with a pitu-
itary source (Cushing’s disease) than with an adre-
nal source. However, because she had an adrenal
nodule and her corticotropin level was on the low
side of the normal range, I elected to perform a rare-
ly used test, an iodocholesterol scan, which was
done at New England Medical Center.
Cortisol-secreting adrenal adenoma and Cushing’s
syndrome.
Cortisol-secreting adrenal adenoma and Cushing’s
syndrome.
 
Dr. Harris:
 
 Dr. Maher, would you show us the imag-
ing study?
 
Dr. Maher:
 
 In iodocholesterol scintigraphy, a ra-
diopharmaceutical agent is injected on day 1, and
peak levels are usually achieved within the adrenal
gland within two days. There is a lot of background
activity at this time, so the best window in which to
obtain an image is between four and five days, when
background activity decays. The images from the
scan obtained on day 5 (Fig. 2) show that there is
increased uptake of the radiopharmaceutical agent
in the left adrenal gland. There is no activity in the
right adrenal gland. The findings suggest a func-
tional left adrenal adenoma.
 
Dr. Grinspoon:
 
 This test indicated that the patient
had an autonomous adrenal nodule, but it did not
entirely rule out the simultaneous occurrence of a
pituitary source of corticotropin and an autono-
mously functioning nodule. Imaging of her head
did not reveal a pituitary tumor, although this would
not rule out the more common source of excess
corticotropin from a very small tumor. Nonetheless,
I referred her for adrenal surgery.
 
Dr. Chin-Lee Wu:
 
 A left adrenalectomy was per-
formed. The adrenal gland contained a well-circum-
scribed, smooth-surfaced mass that was 3 cm in di-
clinical diagnosis
dr.  robert g.  dluhy’s  diagnosis
pathological discussion
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ameter and weighed 20 g. The cut surface is yellow,
smooth, homogeneous, and well demarcated from
the residual normal adrenal cortical tissue (Fig. 3A).
On microscopical examination, the cells form nest-
ed and trabecular patterns and contain abundant
lipid-rich, clear cytoplasm, with small nuclei and
no mitoses (Fig. 3B), and they resemble the cells
seen in the zona fasciculata of the normal adrenal
cortex.
With the increasing use of imaging methods, the
incidental findings of asymptomatic adrenal tumors
provide diagnostic challenges for pathologists as
well as clinicians. The main pathological differential
diagnosis of these tumors includes adrenal cortical
hyperplasia, adenoma, carcinoma, metastatic can-
cer, and less commonly, myelolipoma, lipoma, and
nonfunctional pheochromocytoma. It is not usually
possible to distinguish functional from nonfunc-
tional adrenal cortical tumors on the basis of the
pathological findings.
When a single adrenal cortical mass is found,
the differential diagnosis consists of  adrenal corti-
cal adenoma and carcinoma. Grossly, adrenal corti-
cal adenomas are small (the median size is 2 cm, the
median weight 10 g) and well circumscribed, with
a smooth cut surface, and no necrosis or hemor-
rhage.
 
19
 
 Adrenal cortical carcinomas are large (the
median size is 14 cm, the median weight 510 g),
with an ill-defined border, nodular coarse cut sur-
face containing necrosis, and hemorrhage.
 
20
 
When viewed microscopically, adrenal cortical
carcinomas usually contain atypical mitoses, show
signs of vascular and capsular invasion, and extend
into adjacent adipose tissue.
 
20
 
 The nine histologic
features used to distinguish carcinoma from ade-
noma are a high mitotic rate (≥5 per 50 high-power
fields), atypical mitoses, venous invasion, a high
nuclear grade (Fuhrman grade 3 to 4; on a scale
from 1 to 4, with grade 1 indicating the best prog-
nosis and grade 4 the worst), an absence of cells
with clear cytoplasm (<25 percent of the cells), a
diffuse growth pattern (in more than one third of
 
Figure 2. Posterior Views Obtained by Iodocholesterol 
Scintigraphy, Five Days after Intravenous Administration 
of a Radiopharmaceutical Agent.
 
There is increased uptake of the radiolabeled material 
seen in the left adrenal mass (arrow) and no uptake in 
the right adrenal gland. There is background activity in the 
liver (arrowhead).
 
Figure 3. Tumor of the Adrenal Gland.
 
A gross photograph (Panel A) shows that the tumor is 
well circumscribed, with a yellow-tan, smooth, homoge-
neous cut surface; it is well demarcated from the residual 
normal adrenal cortical tissue. On microscopical exam-
ination (Panel B), the tumor consists of cells arranged in 
nested and trabecular patterns and contains abundant 
lipid-rich, clear cytoplasm. The cells are similar to those 
in the zona fasciculata of the normal adrenal cortex.
A
B
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the tumor), necrosis, sinusoidal invasion, and cap-
sular invasion.
 
21
 
 If three or more of these histolog-
ic features are present, a diagnosis of adrenal corti-
cal carcinoma is made, whereas adrenal cortical
adenomas contain two or fewer of these histologic
features.
 
21,22
 
Fine-needle aspiration biopsy may be useful in
the diagnosis of adrenal incidentaloma after ap-
propriate testing to rule out pheochromocytoma.
Such a biopsy can be useful in distinguishing met-
astatic tumors from primary adrenal tumors. When
adrenal cortical tissue is identified, the differential
diagnosis includes hyperplasia, adenoma, and car-
cinoma. It is not possible to distinguish between
hyperplasia and adenoma on fine-needle aspiration
biopsy. Features such as atypia and mitotic activity
suggest adrenal cortical carcinoma. If the features
of an obvious cancer are found, immunophenotyp-
ing studies can help to distinguish primary cancer
from metastatic cancer in the adrenal gland.
The adrenal cortical tumor in this case was small
and well circumscribed, with no necrosis or hem-
orrhage; histologically, the tumor cells contained
clear, lipid-rich cytoplasm, and no mitoses or other
features of adrenal cortical carcinoma were present.
Thus, the pathological diagnosis was adrenal corti-
cal adenoma.
 
Dr. Harris:
 
 Dr. Grinspoon, could you tell us about
the patient’s postoperative course?
 
Dr. Grinspoon:
 
 Hypoadrenalism developed after
removal of the nodule, thereby indicating that the
adrenal nodule was the source of her cortisol excess.
She was treated with a low-dose glucocorticoid for
three months, and over this time period her adre-
nal function recovered. Her arthritis symptoms
flared up after the cure of her Cushing’s syndrome.
For 15 months after the operation, she required no
antihypertensive medications, but her blood pres-
sure rose again and was stabilized in the normal
range with the administration of lisinopril at 10 mg
daily.
 
Dr. Dluhy:
 
 There is a risk of adrenocortical insuf-
ficiency after adrenalectomy for a cortisol-secreting
tumor, owing to the suppression of the contralateral
adrenal gland. It should be the standard practice
to administer supplemental or stress doses of cor-
tisol intraoperatively and perioperatively, and the
patient should be discharged from the hospital on
a regimen of replacement cortisol therapy. After
tapering and discontinuation of replacement treat-
ment, a cosyntropin stimulation test can be useful
to document recovery of the suppressed adrenal
cortex.
Functional adrenal cortical adenoma.
anatomical diagnosis
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